Instituto Portugues de Reumatologia | Lisbon, Portugal

Research site

(Unclaimed)

Location

7 Rua da Benificiencia, Lisbon, Lisbon, Portugal

Site insights

Top conditions

Top treatments

Upadacitinib

ABT-494

Methotrexate

MTX

Deucravacitinib

Adalimumab

BMS-986165

Baricitinib

Zasocitinib

Cenerimod

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 14 total trials

A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus (OPUS-2)

The goal of this clinical trial is to see how well cenerimod reduces symptoms of Systemic Lupus Erythematous in adult patients with moderate to sever...

Enrolling

Lupus Erythematosus, Systemic

Drug: Cenerimod

Drug: Placebo

A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate (SELECT-COMPARE)

The purpose of this study was to assess efficacy, including inhibition of radiographic progression, and safety with upadacitinib versus placebo and v...

Active, not recruiting

Rheumatoid Arthritis

Drug: Placebo for Upadacitinib

Drug: Upadacitinib

A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines

Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects the joints and skin in people who have psoriasis (PsO).The main aim of the s...

Enrolling

Psoriatic Arthritis

Drug: Active Comparator

Drug: Zasocitinib

A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (POETYK SLE-2)

The purpose of this study is to evaluate the effectiveness and safety of deucravacitinib compared with placebo in an active moderate to severe System...

Enrolling

Systemic Lupus Erythematosus

Drug: Deucravacitinib

Other: Placebo